Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Shord, Stacy S ^a   Patel, Shitalben R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; DRUG METABOLITE; GEMCITABINE; GEMCITABINE DIPHOSPHATE; GEMCITABINE MONOPHOSPHATE; GEMCITABINE TRIPHOSPHATE; MESSENGER RNA; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL IMMORTALIZATION; CELL VIABILITY; CONTROLLED STUDY; DEAMINATION; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECT; ENZYMOLOGY; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL PROLIFERATION; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LUNG NEOPLASMS; PACLITAXEL; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 68149098691     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-76     Document Type: Article

References (31)

1. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. JH Schiller D Harrington CP Belani C Langer A Sandler J Krook J Zhu DH Johnson, N Engl J Med 2002 346 92 98 10.1056/NEJMoa011954 11784875 (Pubitemid 34438899)
2. Correlation of biomarker expression and clinical outcome in a large phase III trial of pemetrexed plus cisplatin or gemcitabine plus cisplatin in chemonaive patients with lcoally advanced or nmetastatic non-small cell lung cancer (NSCLC). G Scagliotti C Kaiser B Bisesma C Manegold U Gatzemeiser P Serwatowski K Syrigos B Balint HJ Smit J Vansteenkiste, J Thorac Oncol 2007 2 S375 10.1097/01.JTO.0000283223.48520.7c
3. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. MQ Baggstrom TE Stinchcombe DB Fried C Poole TA Hensing MA Socinski, J Thorac Oncol 2007 2 845 853 10.1097/JTO.0b013e31814617a2 17805063 (Pubitemid 47361027)
4. Combination chemotherapy of the taxanes and antimetabolites: its use and limitations. CH Smorenburg A Sparreboom M Bontenbal J Verweij, Eur J Cancer 2001 37 2310 2323 10.1016/S0959-8049(01)00309-4 11720823 (Pubitemid 33097466)
5. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. W Plunkett P Huang YZ Xu V Heinemann R Grunewald V Gandhi, Semin Oncol 1995 22 3 10 7481842
6. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. AM Bergman PP Eijk VW Ruiz van Haperen K Smid G Veerman I Hubeek P van den Ijssel B Ylstra GJ Peters, Cancer Res 2005 65 9510 9516 10.1158/0008-5472.CAN-05-0989 16230416 (Pubitemid 41508021)
7. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. JD Davidson L Ma M Flagella S Geeganage LM Gelbert CA Slapak, Cancer Res 2004 64 3761 3766 10.1158/0008-5472.CAN-03-3363 15172981 (Pubitemid 38697284)
8. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. JR Kroep WJ Loves CL van der Wilt E Alvarez L Talianidis E Boven BJ Braakhuis CJ van Groeningen HM Pinedo GJ Peters, Mol Cancer Ther 2002 1 371 376 12477049
9. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. WS Kwon SY Rha YH Choi JO Lee KH Park JJ Jung TS Kim HC Jeung HC Chung, Pharmacogenet Genomics 2006 16 429 438 10.1097/01.fpc.0000204999.29924.da 16708051
10. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780. VW Ruiz van Haperen G Veerman S Eriksson AP Stegmann GJ Peters, Semin Oncol 1995 22 35 41 7481843
11. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. JL Abbruzzese R Grunewald EA Weeks D Gravel T Adams B Nowak S Mineishi P Tarassoff W Satterlee MN Raber, J Clin Oncol 1991 9 491 498 1999720
12. N Andre A Ortiz C Mercier S Giacometti J-M Feuerstein L Camin-Jau J-L BVernar J Ciccolini, Phenotypic determination of CDA status: animal study and application in pediatric oncology Philadelphia AACR 2008
13. Pharmacology and pharmacokinetics of paclitaxel. JG Kuhn, Ann Pharmacother 1994 28 S15 17 7915153
14. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancera randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. H Anderson P Hopwood RJ Stephens N Thatcher B Cottier M Nicholson R Milroy TS Maughan SJ Falk MG Bond, Br J Cancer 2000 83 447 453 10.1054/bjoc.2000.1307 10945489
15. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. M Ranson N Davidson M Nicolson S Falk J Carmichael P Lopez H Anderson N Gustafson A Jeynes G Gallant, J Natl Cancer Inst 2000 92 1074 1080 10.1093/jnci/92.13.1074 10880550 (Pubitemid 30616481)
16. Paclitaxel decreases the accumulation of gemcitabine and its metabolites in human leukemia cells and primary cell cultures. SS Shord JR Camp LA Young, Anticancer Res 2005 25 4165 4171 16309212
17. Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer. SS Shord SR Faucette HH Gillenwater SL Pescatore RL Hawke MA Socinski C Lindley, Cancer Chemother Pharmacol 2003 51 328 336 12721761
18. Comparison of 5 microplate colorimetric assays for in vitro cytotoxicity testing and cell proliferation assays. A Martin M Clynes, Cytotechnology 1993 11 49 58 10.1007/BF00749057 7763636
19. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. TC Chou P Talalay, Adv Enzyme Regul 1984 22 27 55 10.1016/0065-2571(84)90007-4 6382953
20. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. JR Kroep G Giaccone C Tolis DA Voorn WJ Loves CJ Groeningen HM Pinedo GJ Peters, Br J Cancer 2000 83 1069 1076 10.1054/bjoc.2000.1399 10993656
21. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. LL Vindelov IJ Christensen NI Nissen, Cytometry 1983 3 323 327 10.1002/cyto.990030503 6188586
22. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. JK Lamba K Crews S Pounds EG Schuetz J Gresham V Gandhi W Plunkett J Rubnitz R Ribeiro, J Pharmacol Exp Ther 2007 323 935 945 10.1124/jpet.107.128595 17855478 (Pubitemid 350146062)
23. Expression of deoxycytidine kinase in leukaemic cells compared with solid tumour cell lines, liver metastases and normal liver. CL van der Wilt JR Kroep WJ Loves MG Rots CJ Van Groeningen GJ Kaspers GJ Peters, Eur J Cancer 2003 39 691 697 10.1016/S0959-8049(02)00813-4 12628850 (Pubitemid 36287383)
24. Recombinant human cytidine deaminase: expression, purification, and characterization. S Vincenzetti A Cambi J Neuhard E Garattini A Vita, Protein Expr Purif 1996 8 247 253 10.1006/prep.1996.0097 8812871 (Pubitemid 26354672)
25. The intracellular localization of deoxycytidine kinase. P Hatzis AS Al-Madhoon M Jullig TG Petrakis S Eriksson I Talianidis, J Biol Chem 1998 273 30239 30243 10.1074/jbc.273.46.30239 9804782 (Pubitemid 28545489)
26. Intracellular localization of human cytidine deaminase. Identification of a functional nuclear localization signal. A Somasekaram A Jarmuz A How J Scott N Navaratnam, J Biol Chem 1999 274 28405 28412 10.1074/jbc.274.40.28405 10497201 (Pubitemid 29472964)
27. Paclitaxel alters the metabolism of gemcitabine to its active metabolite diflourodeoxycytidine triphosphate. SS Shord JR Camp, Proc Am Soc Clin Oncol 2004 23 149
28. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. C Theodossiou JA Cook J Fisher D Teague JE Liebmann A Russo JB Mitchell, Int J Oncol 1998 12 825 832 9499442
29. Enhancement of gemcitabine-induced apoptosis by restoration of p53 function in human pancreatic tumors. M Cascallo J Calbo G Capella C Fillat M Pastor-Anglada A Mazo, Oncology 2005 68 179 189 10.1159/000086772 16006755 (Pubitemid 41158974)
30. Gene expression ratio of deoxycytidine kinase (dCK) to cytidine deaminase (CDA) corresponds with cytotoxicity in solid tumors in vitro. SS Shord SR Patel, Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 1216 San Diego, CA Philadelphia (PA): AACR 2008
31. Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. V Gandhi W Plunkett, Cancer Res 1990 50 3675 3680 2340517